Multiple Sclerosis (MS)
Multiple sclerosis is one of the most common neurological disorders affecting young and middle-aged people.
There are over 2 million people worldwide with multiple sclerosis. This disease usually occurs in the 30s and is seen more in women.
Multiple sclerosis, they begin with one or more of the following complaints such as loss of sight, double vision, impaired balance, numbness at the corners or legs, speech disorders, dizziness, loss of power at the corners or legs, urination problems, sexual problems. In addition to medical treatments in the treatment of multiple sclerosis, physical therapy and rehabilitation are integral parts of treatment. Multiple sclerosis is not a contagious disease. It is not an illness with familial examples. MS is not a disease that prevents patients from having children.
Multiple Sclerosis is not a fatal disease. Multiple Sclerosis is never a helpless disease.
Multiple Sclerosis (MS) is an important neurological disease that threatens not the life but the quality of life.
SVF Root Cell in Multiple Sclerosis
In multiple sclerosis, stem cell therapy is widespread in Europe and the Far East, especially in the Americas. In patients treated with stem cells, 59% and positive effects were reported.
The goal of stem cell therapy in multiple sclerosis is to try to prevent damage caused by the immune system on one’s own nerve cell and to restore damaged nerve cells by taking advantage of the regenerative function of the stem cells. It helps stop the progression of the stem cell transplant disease, while helping to reduce neurological symptoms.
In the studies done, multiple sclerosis stem cell therapy is observed in the long term, with neurological effects being rapidly improved in the psycho-emotional state of the patient. It has been reported that in the vast majority of patients (93%) they recovered within a very short period of time after transplantation. These healing, diminishment of weakness, vivid appearance, appetite and improvement in morale are the symptoms. In addition, reduction in some psychiatric changes such as depression, phobia and anxiety in some of the patients (63% of the cases), increased confidence in the treatment of the disease, better working capacity, increased concentration (in this respect, to be more successful) happened.
Within 3-6 months after stem cell transplantation, progression of the disease has been reported to be stopped in patients with multiple sclerosis at baseline, but regeneration of the nervous system is a long-term process and requires patience.
- Riordan, N.H., et al. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis (Review Article). Journal of Translational Medicine. 2009; 7:29, 1-9.
- Ng, T.K., et al. Progress of mesenchymal stem cell therapy for neural and retinal diseases. World J. Stem Cells. 2014; 6(2): 111-119.
* Initiation of stem cell therapy is primarily a physician assessment and subsequent patient decision. DOKU BIOTECHNOLOGY is not a treatment practitioner. These results refer to the findings obtained as a result of scientific and clinical studies.